Stock listing
TPEx:6696 Lin BioScience, Inc. (仁新*) 股價
Follow Lin BioScience, Inc. into a list and get an email when it puts out news.
Share price · TPEX:6696
$119.50 TWD -33.00 (-21.6%)
Close on Nov 20, 2026
- Day range
- $110.00 – $156.00 TWDNov 20, 2026
- Volume
- 17.20M sharesNov 20, 2026
- Market cap
- $99.09B TWDAt the close on Nov 20, 2026 · price × 829.2M shares outstanding
- 52-week range
- $24.75 – $207.00 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.26B TWDMedian day 5.36M shares · 8 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:6696 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $119.50 | -33.00 | -21.6% | $155.00 | $156.00 | $110.00 | 17,197,427 | |
| $152.50 | -9.50 | -5.9% | $166.50 | $166.50 | $148.50 | 6,406,617 | |
| $162.00 | -2.50 | -1.5% | $166.50 | $168.00 | $159.50 | 2,375,663 | |
| $164.50 | +0.50 | +0.3% | $166.00 | $168.00 | $159.00 | 2,911,693 | |
| $164.00 | -14.50 | -8.1% | $177.00 | $179.00 | $163.00 | 7,117,107 | |
| $178.50 | +8.50 | +5.0% | $175.00 | $187.00 | $172.50 | 9,126,282 | |
| $170.00 | +4.50 | +2.7% | $164.50 | $173.50 | $161.50 | 6,198,390 | |
| $165.50 | +3.00 | +1.8% | $163.50 | $168.50 | $159.00 | 3,473,481 | |
| $162.50 | +4.50 | +2.8% | $161.00 | $175.50 | $159.00 | 4,079,937 | |
| $158.00 | +11.50 | +7.8% | $150.00 | $160.50 | $150.00 | 3,593,137 | |
| $146.50 | -5.00 | -3.3% | $150.00 | $156.00 | $128.00 | 8,904,010 | |
| $151.50 | -7.00 | -4.4% | $162.00 | $162.50 | $150.50 | 4,654,735 | |
| $158.50 | -2.00 | -1.2% | $162.00 | $164.50 | $157.50 | 3,188,347 | |
| $160.50 | -9.50 | -5.6% | $168.00 | $173.00 | $158.50 | 5,363,870 | |
| $170.00 | +10.50 | +6.6% | $159.00 | $172.00 | $157.50 | 4,311,889 | |
| $159.50 | -2.50 | -1.5% | $161.50 | $163.00 | $153.00 | 3,626,564 | |
| $162.00 | +2.50 | +1.6% | $161.00 | $166.50 | $159.50 | 3,500,310 | |
| $159.50 | +2.00 | +1.3% | $159.00 | $161.50 | $156.00 | 2,750,158 | |
| $157.50 | -4.00 | -2.5% | $162.50 | $163.50 | $155.50 | 4,077,819 | |
| $161.50 | 0.00 | 0.0% | $161.50 | $161.50 | $161.50 | 0 | |
| $161.50 | -9.50 | -5.6% | $171.00 | $172.00 | $161.50 | 3,823,025 | |
| $171.00 | +7.00 | +4.3% | $167.00 | $177.00 | $164.00 | 4,385,476 | |
| $164.00 | +7.00 | +4.5% | $160.00 | $169.50 | $156.00 | 4,321,110 | |
| $157.00 | -9.00 | -5.4% | $163.50 | $166.00 | $149.00 | 9,845,753 | |
| $166.00 | +3.00 | +1.8% | $164.50 | $172.00 | $160.00 | 4,258,603 | |
| $163.00 | -2.50 | -1.5% | $164.50 | $172.50 | $155.00 | 10,131,309 | |
| $165.50 | -5.00 | -2.9% | $172.00 | $172.00 | $163.50 | 6,878,700 | |
| $170.50 | -1.00 | -0.6% | $172.00 | $180.00 | $168.00 | 4,720,343 | |
| $171.50 | -4.50 | -2.6% | $173.00 | $185.00 | $170.00 | 3,654,119 | |
| $176.00 | +3.00 | +1.7% | $175.00 | $179.50 | $172.50 | 2,695,780 | |
| $173.00 | -4.00 | -2.3% | $179.00 | $180.00 | $170.50 | 4,649,657 | |
| $177.00 | +5.00 | +2.9% | $170.50 | $181.00 | $169.00 | 4,693,965 | |
| $172.00 | -10.00 | -5.5% | $180.00 | $184.00 | $170.50 | 11,165,610 | |
| $182.00 | -4.00 | -2.2% | $185.00 | $191.00 | $178.00 | 9,111,353 | |
| $186.00 | -4.50 | -2.4% | $191.00 | $195.50 | $186.00 | 5,644,419 | |
| $190.50 | +4.50 | +2.4% | $189.00 | $194.00 | $186.50 | 4,387,870 | |
| $186.00 | -11.50 | -5.8% | $197.00 | $202.00 | $182.50 | 9,194,139 | |
| $197.50 | +3.50 | +1.8% | $190.00 | $201.00 | $181.00 | 7,770,671 | |
| $194.00 | -1.00 | -0.5% | $197.50 | $207.00 | $190.00 | 14,418,930 | |
| $195.00 | +28.00 | +16.8% | $168.00 | $197.00 | $168.00 | 17,611,754 | |
| $167.00 | +2.00 | +1.2% | $165.50 | $170.00 | $164.50 | 3,654,781 | |
| $165.00 | -2.50 | -1.5% | $168.50 | $170.50 | $160.00 | 5,614,560 | |
| $167.50 | +4.50 | +2.8% | $160.00 | $170.50 | $160.00 | 6,044,991 | |
| $163.00 | -5.00 | -3.0% | $170.00 | $171.50 | $160.00 | 9,644,479 | |
| $168.00 | +1.00 | +0.6% | $167.00 | $177.00 | $166.00 | 10,525,183 | |
| $167.00 | +4.00 | +2.5% | $163.50 | $170.00 | $155.00 | 8,317,730 | |
| $163.00 | -5.00 | -3.0% | $167.50 | $169.00 | $150.00 | 14,946,462 | |
| $168.00 | -0.50 | -0.3% | $168.00 | $175.00 | $158.00 | 11,461,152 | |
| $168.50 | -11.00 | -6.1% | $179.00 | $180.00 | $166.00 | 12,412,616 | |
| $179.50 | +5.00 | +2.9% | $177.00 | $196.00 | $159.00 | 24,866,858 | |
| $174.50 | +29.00 | +19.9% | $146.00 | $200.00 | $134.00 | 40,922,578 | |
| $145.50 | +27.50 | +23.3% | $120.00 | $145.50 | $112.50 | 29,987,508 | |
| $118.00 | +21.40 | +22.2% | $97.00 | $120.50 | $95.00 | 26,567,036 | |
| $96.60 | +9.30 | +10.7% | $85.40 | $98.90 | $82.20 | 14,925,560 | |
| $87.30 | -8.40 | -8.8% | $96.90 | $99.00 | $86.70 | 17,533,685 | |
| $95.70 | +2.00 | +2.1% | $96.00 | $109.00 | $89.70 | 22,928,381 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 | |
| $93.70 | 0.00 | 0.0% | $93.70 | $93.70 | $93.70 | 0 |
Splits
1 split · TPEX:6696 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 10-for-1 | Split |
- Ticker
- TPEx:6696
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
What changed lately
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 44 slides
Latest news
Lin BioScience, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in all · newest Nov 27, 2024 · oldest 2024
- Decks
- 10 decks · latest July 2026
Valuation
Price/book 9.3× against a median of 3.6×: 9th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $82.49B TWD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 9.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lin BioScience, Inc. · TPEX:6696 | US$3.01B | US$2.50B | n/a | n/a | n/a | 9.3× | n/a | 0.0× | n/a |
| Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX | US$3.35B | US$2.58B | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.21 |
| Iovance Biotherapeutics, Inc. · NASDAQ:IOVA | US$3.19B | US$2.86B | n/a | 7.5× | n/a | 3.9× | −58.2% | 0.1× | 1.62 |
| AbCellera Biologics Inc. · NASDAQ:ABCL | US$3.16B | US$2.53B | n/a | 37.3× | n/a | 3.0× | −218.5% | 0.1× | 2.42 |
| Viking Therapeutics, Inc. · NASDAQ:VKTX | US$3.16B | US$2.20B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.31 |
| Legend Biotech Corp. · NASDAQ:LEGN | US$2.97B | US$2.28B | n/a | 1.7× | 27.0× | 2.3× | −0.0% | 0.1× | 0.75 |
| Denali Therapeutics Inc. · NASDAQ:DNLI | US$2.96B | US$2.69B | n/a | 126× | n/a | 3.2× | n/a | 0.3× | 1.30 |
| Dyne Therapeutics, Inc. · NASDAQ:DYN | US$2.90B | US$1.97B | n/a | n/a | n/a | 3.1× | n/a | 0.2× | 1.51 |
| Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180 | US$2.88B | US$2.99B | n/a | 8.0× | n/a | 3.2× | −35.0% | 0.7× | n/a |
| SELLAS Life Sciences Group, Inc. · NASDAQ:SLS | US$2.78B | US$2.65B | n/a | n/a | n/a | 21.1× | n/a | 0.0× | 2.19 |
| HLB Co., Ltd. · KRX:028300 | US$2.69B | US$2.69B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Median of the others | US$2.96B | US$2.62B | 22.4× | 27.0× | 3.6× | −58.2% | 0.1× | 1.41 |
Team and board
Officers
| Officer | Role |
|---|---|
| Serena Chen | CFO |
| Irene Wang | President & CSO |
Board
| Director | Role |
|---|---|
| Tom Lin | Chairman |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 44 slides | July 2026 |
| Investor Presentation (February 2026) | Investor deck | 44 slides | February 2026 |
| Investor Presentation (September 2025) | Investor deck | 37 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 37 slides | July 2025 |
| Investor Presentation (January 2025) | Investor deck | 35 slides | January 2025 |
| Investor Presentation (December 2023) | Investor deck | 33 slides | December 2023 |
| Investor Presentation (December 2023) | Investor deck | 31 slides | December 2023 |
| Investor Presentation (November 2023) | Investor deck | 30 slides | November 2023 |
| Investor Presentation (September 2022) | Investor deck | 30 slides | September 2022 |
| Investor Presentation (2022) | Investor deck | 23 slides | Apr 14, 2022 |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | 20.2M | 17.9M | 11.2M | 4.39M | 4.08M | 4.31M | |
| Gross profit | -20.2M | -17.9M | -11.2M | -4.39M | -4.08M | -4.31M | |
| Research and development | 1.61B | 1.10B | 854.1M | 320.9M | 244.8M | 145.0M | 193.3M |
| Selling, general and administrative | 1.24B | 355.9M | 240.5M | 120.0M | 89.6M | 49.1M | |
| Operating income | -2.86B | -1.46B | -1.10B | -445.1M | -338.3M | -197.0M | -238.2M |
| Depreciation and amortization | 23.8M | 20.2M | 17.9M | 11.2M | 4.39M | 4.08M | 4.31M |
| EBITDA | -2.83B | -1.44B | -1.08B | -434.0M | -333.9M | -192.9M | -233.9M |
| Interest expense | 1.02M | 1.00M | 1.21M | 875.0K | 71.0K | 261.0K | |
| Income before tax | -2.64B | -1.33B | -1.09B | -477.9M | -490.4M | -174.8M | -240.0M |
| Income tax | 69.6M | -29.7M | -18.4M | -9.51M | -23.0M | -4.78M | |
| Net income | -1.36B | -744.3M | -687.2M | -313.5M | -434.7M | -151.8M | -235.3M |
| Earnings per share, basic | -1.65 | -9.47 | -9.23 | -4.37 | -6.23 | -2.39 | -3.87 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.9B | 1.49B | 3.26B | 1.65B | 806.8M | 1.09B | 117.1M |
| Short-term investments | 4.38B | 3.72B | |||||
| Receivables | 18.9M | 25.5M | 110.0K | 1.49M | 27.0K | 96.0K | |
| Current assets | 16.5B | 5.35B | 3.42B | 1.67B | 819.5M | 1.11B | 129.6M |
| Total assets | 25.4B | 5.53B | 3.60B | 1.85B | 923.2M | 1.22B | 248.7M |
| Current liabilities | 282.8M | 155.3M | 138.7M | 79.9M | 470.3M | 306.6M | 100.8M |
| Total debt | 34.0M | 42.9M | 46.5M | 2.24M | 5.15M | 67.9M | |
| Total liabilities | 291.2M | 173.2M | 167.7M | 116.1M | 470.3M | 308.9M | 106.0M |
| Shareholders' equity | 10.7B | 2.85B | 2.14B | 1.23B | 541.6M | 912.3M | 141.8M |
| Shares outstanding | 828.3M | 78.6M | 74.5M | 71.7M | 69.8M | 63.5M | 60.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -1.44B | -1.02B | -1.01B | -361.0M | -289.8M | -180.6M | -209.7M |
| Capital spending | -8.18M | -7.35M | -1.97M | -22.4M | -2.12M | -573.0K | -2.34M |
| Free cash flow | -1.45B | -1.03B | -1.01B | -383.4M | -292.0M | -181.2M | -212.0M |
| Cash from investing | -3.55B | 1.87M | -24.1M | -1.48M | 204.0K | 99.0M | |
| Cash from financing | 2.66B | 2.64B | 1.13B | 28.3M | 1.16B | 57.6M | |
| Change in cash | 10.4B | -1.77B | 1.62B | 838.4M | -285.4M | 975.1M | -50.8M |
Cap table
Built by 6ix from Lin BioScience, Inc.’s releases
- Common shares
- 829,200,000
- Fully diluted
- 829,200,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 829,200,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 829,200,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Irene Wang | President & CSO · Since at least Nov 27, 2024 |
| Serena Chen | CFO · Since at least Nov 27, 2024 |
| Tom Lin | Chairman · Since at least Nov 27, 2024 |
Log in to ask 6ix AI your own questions about Lin BioScience, Inc.